Compare CAPR & YORW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | YORW |
|---|---|---|
| Founded | 2005 | 1816 |
| Country | United States | United States |
| Employees | N/A | 104 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Water Supply |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 552.3M |
| IPO Year | 2011 | 1994 |
| Metric | CAPR | YORW |
|---|---|---|
| Price | $8.37 | $30.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | ★ $44.63 | $34.00 |
| AVG Volume (30 Days) | ★ 3.5M | 99.2K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 3.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $77,488,000.00 |
| Revenue This Year | N/A | $11.78 |
| Revenue Next Year | $3.31 | $4.95 |
| P/E Ratio | ★ N/A | $37.49 |
| Revenue Growth | N/A | ★ 3.37 |
| 52 Week Low | $2.96 | $28.26 |
| 52 Week High | $40.37 | $34.81 |
| Indicator | CAPR | YORW |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 27.59 |
| Support Level | $8.18 | $29.47 |
| Resistance Level | $9.79 | $32.04 |
| Average True Range (ATR) | 0.55 | 0.62 |
| MACD | 0.07 | -0.37 |
| Stochastic Oscillator | 9.85 | 9.57 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
The York Water Co is the investor-owned water utility in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. The company also owns and operates three wastewater collection systems and twelve wastewater collection and treatment systems. The company operates within its franchised water and wastewater territory, which covers portions of municipalities within four counties in south-central Pennsylvania. It provides services to diversified, manufacturing such items as fixtures and furniture, electrical machinery, food products, paper, ordnance units, textile products, air conditioning systems, laundry detergent, barbells, and motorcycles.